Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer based controlled release tablets of aceclofenac to simultaneously enhance the solubility and bioavailability
Affiliations: [a] Drug Delivery and Cosmetics Laboratory (DDCL), Gomal Centre of Pharmaceutical Sciences (GCPS), Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan
| [b] Department of Oncology, Combined Military Hospital (CMH), Rawalpindi, Pakistan
| [c] Department of Pharmaceutical Sciences and Nanomedicine, California Innovations Corporation, San Diego, California, USA
Correspondence:
[*]
Corresponding author: Muhammad Khalid Khan, Drug Delivery and Cosmetics Laboratory (DDCL),Gomal Centre of Pharmaceutical Sciences (GCPS), Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan. khalid.gomalian@gmail.com
Abstract: The aim of this study was to enhance the solubility of Aceclofenac with a new polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer (Soloplus®) and formulate it in controlled release (CR) tablet dosage form by direct compression method with HPMC K-15. Solid dispersions were prepared in different ratio of Aceclofenac and Soloplus® as F1, F2 and F3 with different polymer ratios i.e. 30%, 50%, and 70% respectively. All the quality control tests were performed for the prepared controlled release tablets. Drug polymer interaction studies of Aceclofenac and Soloplus® were carried using FTIR and XRD. Dissolution study was carried out against Alkaris® as a standard reference. The formulation F3 showed optimum results and followed zero order kinetics. The Soloplus® improved the solubility of the drug and the CR formulation enhanced the delivery in a sustained manner. Hence, the CR formulation enhanced the delivery of aceclofenac in a sustained manner, thereby an efficient drug delivery may lead to an effective anti-inflammatory activity.
